文献速递泌尿生殖与妇科肿瘤放疗

大前列腺体积对前列腺癌中度大分割放疗疗效与毒性的影响

Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-09-14

该研究纳入2008年8月20日至2018年1月31日在退伍军人事务医疗中心接受中度大分割放疗的472例前列腺癌患者,将前列腺计划靶区体积处于最高四分位者定义为大前列腺计划靶区体积组。结果显示大前列腺计划靶区体积不影响疗效,但与晚期2级及以上泌尿生殖毒性风险增加和发生时间提前相关。

要点

  • 大前列腺计划靶区体积(PTV>138.4 cm3)患者晚期2级及以上泌尿生殖毒性发生率较高(59% vs 48%,P=.03)。
  • 大前列腺计划靶区体积与晚期2级及以上泌尿生殖毒性发生时间提前相关(HR 1.36;95%CI 1.00-1.86;P=.047)。
  • 大前列腺计划靶区体积未影响总生存或无生化复发生存。

核心结论

  • 大前列腺计划靶区体积不影响前列腺癌中度大分割放疗的疗效,但与晚期2级及以上泌尿生殖毒性风险增加和发生时间提前相关。

研究设计与样本

  • 回顾性识别2008年8月20日至2018年1月31日在退伍军人事务医疗中心接受中度大分割放疗的前列腺癌患者,共纳入472例。
  • 前列腺计划靶区体积处于最高四分位者归为大前列腺计划靶区体积组(PTV>138.4 cm3),比较两组急性和晚期泌尿生殖及胃肠道毒性事件。
  • 采用多变量分析估计各因素对毒性的影响,并用Kaplan-Meier法估计总生存、无生化复发生存和免于晚期泌尿生殖/胃肠道毒性。

主要发现

  • 93%的患者接受70 Gy分2.5 Gy/次照射,75%接受雄激素剥夺治疗,中位随访69个月。
  • 大前列腺计划靶区体积组晚期2级及以上泌尿生殖毒性发生率为59%,无大前列腺计划靶区体积组为48%(P=.03)。
  • 大前列腺计划靶区体积与晚期2级及以上泌尿生殖毒性发生时间提前相关(HR 1.36;95%CI 1.00-1.86;P=.047);雄激素剥夺治疗使用(HR 1.60;95%CI 1.13-2.27;P=.01)和较高的基线美国泌尿协会症状评分(OR 1.03;95%CI 1.02-1.05;P<.001)亦相关。
  • 2年时,大前列腺计划靶区体积组免于晚期2级及以上泌尿生殖毒性为46%(95%CI 47%-54%),无大前列腺计划靶区体积组为61%(95%CI 55%-65%)(P=.04)。
  • 大前列腺计划靶区体积组晚期3级泌尿生殖毒性为7%,无大前列腺计划靶区体积组为4%;两组总生存和无生化复发生存无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of prostate volume on outcomes after moderately hypofractionated radiation therapy (mHFRT) for prostate cancer. METHODS AND MATERIALS: Prostate cancer patients treated with mHFRT at a Veteran's Affairs Medical Center from August 20, 2008, to January 31, 2018, were identified. Patients were placed into a large prostate planning target volume (LPTV) cohort if their prostate PTV was in the highest quartile. Acute/late genitourinary (GU) and gastrointestinal toxicity events among patients with and without LPTV were compared. Multivariable analyses estimated the effect of factors on toxicity. Overall survival, biochemical recurrence-free survival, and freedom from late GU/gastrointestinal toxicity of patients with and without LPTV were estimated via Kaplan-Meier. RESULTS: Four hundred and seventy-two patients were included. Ninety-three percent received 70 Gy in 2.5 Gy fractions; 75% received androgen deprivation therapy. Median follow-up was 69 months. Patients with LPTV (PTV >138.4 cm3) had a higher late 2 + GU toxicity compared with those without (59% vs 48%, P = .03). Earlier time to late 2 + GU toxicity was associated with LPTV (hazard ratio 1.36; 95% confidence interval [CI], 1.00-1.86; P = .047), androgen deprivation therapy use (hazard ratio 1.60; 95% CI, 1.13-2.27; P = .01), and higher baseline American Urologic Association symptom score (odds ratio 1.03; 95% CI, 1.02-1.05; P < .001). At 2 years, freedom from late 2 + GU toxicity was 46% (95% CI, 47%-54%) for those with LPTV versus 61% (95% CI, 55%-65%) for those without (P = .04). Late grade 3 GU toxicity was 7% for those with LPTV and 4% for those without. No differences in overall survival or biochemical recurrence-free survival were observed between patients with or without LPTV. CONCLUSIONS: LPTV did not affect efficacy of mHFRT for prostate cancer; however, it was associated with increased risk and earlier onset of late grade 2 + GU toxicity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Natesan D, Carpenter DJ, Floyd W, et al. Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer. Adv Radiat Oncol. 2021. PMID: 35387417. doi:10.1016/j.adro.2021.100805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。